Filing excerpt
Companion animal operational revenue was flat, primarily due to increased sales of our parasiticides portfolio and our mAb products for pain with the launch of Lenivia® and Portela™, the company's long-acting monoclonal antibody pain products, as well as an increase in demand for small animal diagnostics, offset by decreased sales of key dermatology products.